Masterclass: Navigating Licensing, IP & BD Partnerships in Therapeutics

Actions Panel

Masterclass: Navigating Licensing, IP & BD Partnerships in Therapeutics

Inviting venture-backed therapeutic companies to join us for a 2-day immersive masterclass.

By Ontario Bioscience Innovation Organization

When and where

Date and time

Wed, Jun 21, 2023 8:00 AM - Thu, Jun 22, 2023 6:00 PM EDT


Mintz, 200 Bay St, RBC Plaza South Tower, 28th Floor. Toronto, ON M5J 2J1 Mintz 200 Bay St., RBC Plaza South Tower, 28th Floor Toronto, ON M5J 2J1 Canada

Refund Policy

No Refunds

About this event

  • 1 day 10 hours
  • Mobile eTicket

In partnership with Mintz, Novateur Academy and OBIO® invite venture-backed therapeutic companies to join us for a 2-day immersive masterclass on preparing for pharma business development, IP licensing strategy, deal structure, term sheets, valuation, negotiation & relationship management. These interactive sessions & case studies will be led by experienced pharma & biotech executives. The event will culminate with case-based pitches and mock licensing negotiations judged by pharma BD executives, followed by a networking reception.

Day 1 – 8am to 6pm will consist of lectures, case studies, and panels; from 6-8pm we will provide dinner and work in teams of 5 to build a mock business licensing pitch deck

Day 2 – 8am to 11am we’ll finish the course content; 11am-4pm will be the mock licensing negotiations in your teams; 4-6pm reception

Confirmed Speakers and Facilitators:

  • Ali Ardakani - Chair Life Sciences BC; Associate Creative CDL; Managing Director, Novateur Ventures
  • Anne Stevens - VP of BD, AbCellera; formerly Director, Aequus Pharmaceuticals
  • Arpita Maiti - Head of Immunology Search & Evaluation , AbbVie; formerly Global Head Emerging Sciences, Pfizer
  • Dan Zheng - Sr. Director for Oncology BD, Takeda; formerly Sr. Director Global Transactions, Sanofi
  • David Kennard - Sr. Advisor BD, Novateur; formerly Corp. Development, Gilead Sciences
  • David Poon - Chief Business Officer, Gandeeva Therapeutics; formerly VP of BD, Zymeworks
  • Dozie Amuzie - Head, JLabs Canada
  • Julia Pomoransky - Sr. Director BD, Turnstone Biologics
  • Kuldeep Neote - EIR at UHN and FACIT; formerly VP External Innovations, Eli Lilly
  • Lorraine Hurding - Global Diagnostics Partnering Lead for Strategy & Transactions, Roche
  • Maura Campbell - CEO, OBIO; formerly VP of IP & Contracts, Turnstone Biologics
  • Mike Foorer - VP of BD, AmacaThera; formerly Director Corp. Development, SteriMax
  • Parimal Nathwani - CEO, Toronto Innovation Acceleration Partners
  • Rebecca Ross, Director, Credit Solutions at Life Science & Healthcare SVB
  • Thomas Digby - IP Advisor, Novateur Ventures; formerly Head IP, Novartis
  • Yvonne Joseph - BD Partnerships, Novateur Ventures; formerly Sr. Lead BD, Daewoong Pharmaceuticals

About the organizer